Darren S Cline's Net Worth
$5.1 Million
Who is Darren S Cline?
Darren S Cline has an estimated net worth of $5.1 Million. This is based on reported shares across multiple companies, which include SEATTLE GENETICS INC /WA, GW PHARMACEUTICALS PLC, Pyxis Oncology, Inc., PLIANT THERAPEUTICS, INC., IMPEL PHARMACEUTICALS INC, and STEMLINE THERAPEUTICS INC.
SEC CIK
Darren S Cline's CIK is 0001633639
Past Insider Trading and Trends
2018 was Darren S Cline's most active year for acquiring shares with 11 total transactions. Darren S Cline's most active month to acquire stocks was the month of July. 2018 was Darren S Cline's most active year for disposing of shares, totalling 18 transactions. Darren S Cline's most active month to dispose stocks was the month of April. 2016 saw Darren S Cline paying a total of $427,260.88 for 84,428 shares, this is the most they've acquired in one year. In 2016 Darren S Cline cashed out on 40,565 shares for a total of $1,106,409.93, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
SEATTLE GENETICS INC /WA (SGEN) No price found
EVP, CommercialDarren S Cline owns 72,556 units of Common Stock. In the year 2015 Darren S Cline filed a total of 28 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -8.80% | -7.00K |
$62.88 | -$440,160.00 | 72.56K |
Nov 29
| |||
Form 4
| -4.98% | -4.17K |
$56.68 | -$236,204.31 | 79.56K |
Nov 21
| |||
Form 4
| +28.65% | 18.64K |
—
|
—
| 83.72K |
Aug 30
| |||
Form 4
| -6.85% | -4.78K |
$74.23 | -$355,124.93 | 65.08K |
Scheduled
|
Aug 27
| ||
Form 4
| -2.74% | -1.97K |
$49.07 | -$537,778.35 | 69.86K |
Jun 12
| |||
Form 4
|
—
|
0
|
$35.77 | -$352,192.60 | 71.83K |
May 9
| |||
Form 4
| -5.27% | -4.00K |
$53.81 | -$215,238.40 | 71.83K |
May 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 20
| |||
Form 4
| -1.81% | -1.40K |
$55.58 | -$77,755.86 | 75.83K |
Scheduled
|
Feb 5
| ||
Form 4
| +6.96% | 5.02K |
$33.94 | -$100,851.78 | 77.23K |
Sep 6
| |||
Form 4
| -6.06% | -4.66K |
$35.49 | -$343,803.09 | 72.21K |
Aug 31
| |||
Form 4
| -2.27% | -1.79K |
$47.89 | -$85,635.37 | 76.87K |
Scheduled
|
Aug 28
| ||
Form 4
| +27.57% | 17K |
—
|
—
| 78.66K |
Aug 17
| |||
Form 4
|
—
|
0
|
$33.83 | -$184,350.00 | 61.66K |
Aug 7
| |||
Form 4
| +5.30% | 3.1K |
$16.41 | $50,871.00 | 61.6K |
Dec 16
| |||
Form 4
| +4.95% | 2.76K |
$43.92 | -$321,866.16 | 58.5K |
Dec 13
| |||
Form 4
| +8.08% | 4.17K |
$15.46 | $64,421.82 | 55.74K |
Sep 9
| |||
Form 4
| -9.47% | -5.40K |
$46.01 | -$248,307.10 | 51.58K |
Sep 6
| |||
Form 4
| +39.05% | 16K |
—
|
—
| 56.97K |
Aug 27
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Aug 25
| |||
Form 4
| -4.15% | -1.77K |
$46.59 | -$82,651.90 | 40.97K |
Scheduled
|
Aug 22
| ||
Form 4
| +28.98% | 9.77K |
$42.02 | -$93,756.66 | 43.48K |
Scheduled
|
Aug 20 - Aug 25
| ||
Form 4
| -7.30% | -3.37K |
$42.07 | -$141,616.71 | 42.75K |
Jun 2
| |||
Form 4
| +22.27% | 8.4K |
—
|
—
| 46.11K |
Mar 1
| |||
Form 4
| -13.27% | -5.77K |
$45.68 | -$263,547.53 | 37.71K |
Nov 11
| |||
Form 4
| +28.98% | 9.77K |
$42.02 | -$93,756.66 | 43.48K |
Scheduled
|
Aug 20 - Aug 25
| ||
Form 4
| -18.46% | -7.50K |
$38.65 | -$289,875.75 | 33.13K |
Mar 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GW PHARMACEUTICALS PLC No price found
U.S. Chief Commercial OfficerDarren S Cline used to own units in Ordinary Shares but no longer holds any shares there. In the year 2019 Darren S Cline filed a total of 7 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -5.56K |
—
|
—
|
0
|
May 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
∞
| 9.16K |
$2.07 | $18,980.83 | 5.56K |
May 28
| |||
Form 4
|
∞
| 29.42K |
—
| $38.25 | 29.42K |
May 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Pyxis Oncology, Inc. (PYXS) Snapshot price: $3.45
InvestorDarren S Cline owns 251,405 units of Common Stock which is worth $867,347.25. From 2021 to 2024 Darren S Cline acquired a total of 251,405 shares in Pyxis Oncology, Inc. at a cost of $93,885.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +16.29% | 35.22K |
—
|
—
| 251.41K |
Mar 26
| |||
Form 4
| +181.38% | 139.35K |
—
|
—
| 216.19K |
Mar 24
| |||
Form 4
| +668.31% | 66.83K |
—
|
—
| 76.83K |
Mar 31
| |||
Form 4
|
∞
| 10K |
$9.39 | $93,885.00 | 10K |
Dec 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
PLIANT THERAPEUTICS, INC. (PLRX) Snapshot price: $12.87
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
IMPEL PHARMACEUTICALS INC (IMPL) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||